These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23764196)

  • 1. NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.
    Prague M; Commenges D; Guedj J; Drylewicz J; Thiébaut R
    Comput Methods Programs Biomed; 2013 Aug; 111(2):447-58. PubMed ID: 23764196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum likelihood estimation in dynamical models of HIV.
    Guedj J; Thiébaut R; Commenges D
    Biometrics; 2007 Dec; 63(4):1198-206. PubMed ID: 17489970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian approach to parameter estimation in HIV dynamical models.
    Putter H; Heisterkamp SH; Lange JM; de Wolf F
    Stat Med; 2002 Aug; 21(15):2199-214. PubMed ID: 12210633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.
    Lavielle M; Mentré F
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):229-49. PubMed ID: 17211713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Bayesian and maximum-likelihood inference of population genetic parameters.
    Beerli P
    Bioinformatics; 2006 Feb; 22(3):341-5. PubMed ID: 16317072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population stochastic modelling (PSM)--an R package for mixed-effects models based on stochastic differential equations.
    Klim S; Mortensen SB; Kristensen NR; Overgaard RV; Madsen H
    Comput Methods Programs Biomed; 2009 Jun; 94(3):279-89. PubMed ID: 19268387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.
    Bertrand J; Comets E; Mentre F
    J Biopharm Stat; 2008; 18(6):1084-102. PubMed ID: 18991109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical identifiability of HIV dynamics models.
    Guedj J; Thiébaut R; Commenges D
    Bull Math Biol; 2007 Nov; 69(8):2493-513. PubMed ID: 17557186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.
    Samson A; Lavielle M; Mentré F
    Stat Med; 2007 Nov; 26(27):4860-75. PubMed ID: 17562540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data.
    Stijnen T; Hamza TH; Ozdemir P
    Stat Med; 2010 Dec; 29(29):3046-67. PubMed ID: 20827667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bayesian approach to joint mixed-effects models with a skew-normal distribution and measurement errors in covariates.
    Huang Y; Dagne G
    Biometrics; 2011 Mar; 67(1):260-9. PubMed ID: 20486924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-linear mixed-effects models with stochastic differential equations: implementation of an estimation algorithm.
    Overgaard RV; Jonsson N; Tornøe CW; Madsen H
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):85-107. PubMed ID: 16175312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
    Janus N; Launay-Vacher V; Izzedine H; Karie S; Laville I; Deray G
    Med Mal Infect; 2007 Dec; 37(12):832-4. PubMed ID: 17997253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Dailly E; Raffi F; Biron C; Allavena C; Jolliet P
    Fundam Clin Pharmacol; 2008 Feb; 22(1):101-4. PubMed ID: 18251726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian and maximum likelihood estimation of genetic maps.
    York TL; Durrett RT; Tanksley S; Nielsen R
    Genet Res; 2005 Apr; 85(2):159-68. PubMed ID: 16174334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
    Funatogawa T; Funatogawa I
    J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian analysis of growth curves using mixed models defined by stochastic differential equations.
    Donnet S; Foulley JL; Samson A
    Biometrics; 2010 Sep; 66(3):733-41. PubMed ID: 19912169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.